Establishing an EGFR mutation screening service for non-small cell lung cancer – Sample quality criteria and candidate histological predictors

2012 ◽  
Vol 48 (1) ◽  
pp. 61-67 ◽  
Author(s):  
Alexandra F. Leary ◽  
David Gonzalez de Castro ◽  
Andrew G. Nicholson ◽  
Sue Ashley ◽  
Andrew Wotherspoon ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Egfr Mutation ◽  
Mutation Screening ◽  
Quality Criteria ◽  
Small Cell ◽  
Screening Service ◽  
Small Cell Lung ◽  
Lung Cancer Sample ◽  
Cancer Sample

EGFR mutation screening in non-small cell lung cancer: Results from an access program in Brazil.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 1526-1526 ◽  
Author(s):  
Luciola De Barros Pontes ◽  
Carlos E Bacchi ◽  
Eduardo M Queiroga ◽  
Tony Piha ◽  
Paulo Andre Miranda ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Mutation Screening ◽  
Small Cell ◽  
Small Cell Lung ◽  
Access Program

60 Afatinib in EGFR mutation positive advanced non-small cell lung cancer

Lung Cancer ◽  
2016 ◽  
Vol 91 ◽  
pp. S22
Author(s):  
R.S. Davies ◽  
A.E. Brewster ◽  
M.R. Button ◽  
J.F. Lester
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation

2020 ◽  
Vol 16 (21) ◽  
pp. 1537-1547
Author(s):  
Fumio Imamura ◽  
Madoka Kimura ◽  
Yukihiro Yano ◽  
Masahide Mori ◽  
Hidekazu Suzuki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Kinase Inhibitors ◽  
Egfr Mutation ◽  
Acquired Resistance ◽  
Small Cell ◽  
Small Cell Lung ◽  
T790m Mutation ◽  
Clinical Trial Registration

Aim: Osimertinib is a key drug for EGFR mutation-positive non-small-cell lung cancer (NSCLC). As the hazards ratio of overall survival in comparison with first-generation EGFR-tyrosine kinase inhibitors was almost similar between FLAURA and ARCHER 1050, salvage use of osimertinib is still a treatment option. Patients & methods: We retrospectively analyzed the clinical courses of EGFR mutation-positive NSCLC patients who were potential candidates for salvage osimertinib. Results: Among 524 patients enrolled from five hospitals, 302 patients underwent biopsy, with 52.6% detection rate of T790M. Osimertinib was administered in 93.6% of the T790M-positive patients. The overall response rate and median progression-free survival time of osimertinib were calculated with 147 patients, to be 55.6% and 17.2 months, respectively. Conclusion: Osimertinib is active for T790M-driven acquired resistance in EGFR-mutant NSCLC, but the detection of T790M was unsatisfactory. Clinical Trial Registration: UMIN000028989 (UMIN Clinical Trials Registry)

Sign in / Sign up

Export Citation Format

Share Document